Healthcare products company Johnson & Johnson (J&J) (NYSE:JNJ) on Tuesday announced positive topline results from the Phase 3 MARIPOSA study, demonstrating that the combination of RYBREVANT (amivantamab-vmjw) and LAZCLUZE (lazertinib) significantly improved overall survival (OS) compared to osimertinib as a first-line treatment for patients with EGFR-mutated non-small cell lung cancer (NSCLC).

This is the first and only regimen to show a survival benefit over the current standard of care in this setting. The median OS improvement is expected to exceed one year.

The MARIPOSA study evaluated RYBREVANT plus LAZCLUZE in 1,074 patients. OS was a key secondary endpoint, and these results build upon previously reported positive data on progression-free survival. J&J noted that the safety profile of the combination was generally consistent with the individual treatments.

These OS results will be presented at an upcoming major medical meeting and shared with global health authorities.